2024 Volume 36 Issue 4 Pages 244-250
Psoriatic arthritis（PsA）is closely associated with a reduction in quality of life（QOL）, akin to rheumatoid arthritis, and delays in diagnosis can result in progressive joint destruction and long-term physical disability. Early diagnosis necessitates a thorough understanding of the key clinical manifestations of PsA. This includes not only the assessment of dermatological and nail lesions, present in up to 90% of PsA patients, but also a comprehensive evaluation of peripheral and axial joint involvement through detailed medical history, physical examination, and advanced imaging techniques.
In terms of treatment, a treat-to-target（T2T）approach, informed by recent advancements in pharmacotherapy, is essential. Treatment strategies should be personalized, considering individual disease activity（including axial involvement）and patient-specific factors, such as the presence of comorbidities. It is critical that treatment decisions are made collaboratively between the clinician and the patient, with a careful selection of therapeutic agents, including molecular targeted therapies, based on their pharmacological profiles. This discussion will be grounded in the EULAR treatment recommendations updated in 2023.
